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Abstract
Carcinosarcoma of the breast, often referred to as metaplastic carcinoma of the breast, is a rare
malignancy with two distinct cell lines described as a breast carcinoma of ductal type with a
sarcoma-like component. Clinically, carcinosarcoma of the breast is an aggressive breast cancer.
The prognosis for carcinosarcoma of the breast is less favorable compared to more common types
of breast cancer such as infiltrating ductal or lobular carcinoma. Currently, the evaluation of breast
carcinoma includes hormone receptor analysis of the tumor tissue, with those positive for estrogen
or progesterone responding better to both hormonal and chemotherapy.
Trastuzumab (Herceptin®) is available as an adjunct treatment for tumors which over-express the
HER2/neu gene. Typically, metaplastic carcinomas of the breast do not express the estrogen or
progesterone receptors and do not over-express the HER2/neu oncogene. As a result of this
"triple negative" phenotype, such tumors tend to be more aggressive and are unlikely to respond
to targeted therapy with Herceptin. The epidermal growth factor receptor HER-1/EGFR protein
is expressed in the majority of metaplastic carcinomas and thus may serve as a potential therapeutic
target for EGFR inhibitors such as gefitinib and cetuximab. The two cases we describe exemplify
the aggressive nature of carcinosarcoma of the breast and support the findings that this tumor type
does not express the common receptors found in other breast carcinomas. These case reports
also emphasize the need for investigating the role for blockade of the HER-1/EGFR receptor with
targeted therapies when found to be over-expressed in the primary tumor.
Case presentation
Patient 1
This patient is a 48 year old female who was admitted
with a large fungating right breast mass which measured
22 × 20 cm and elevated 12 cm above the skin surface
(Figure 1). The patient stated that the mass began as a very
small "bump" that she believed was a cyst. One year prior
she had been evaluated by her primary care physician who
described a bulging, red breast mass in the upper outer
quadrant which measured at least 8 cm. Core biopsies
were performed and the pathology revealed a high-grade
malignant neoplasm with dominant features of carci-
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chose to not undergo treatment and allowed the mass to
enlarge with resultant ulceration of the mass through the
skin with centralized necrosis and bleeding of the mass.
The patient's associated symptoms included a 50 pound
weight loss over the previous 6 months with intermittent
low-grade fevers.
The patient's past medical history was significant for
hypertension and left ear deafness. No significant surgical
history was reported and her family history was not signif-
icant for malignancies in any first degree relatives. Physi-
cal examination revealed a cachetic female in significant
pain with a large, extensively necrotic mass on the right
anterolateral breast and chest wall. The necrotic tissue was
on an erythematous, dense mound of tissue that extended
to the lateral and central chest wall. No cervical, supracla-
vicular, left axillary or inguinal lymphadenopathy was
appreciated on physical exam. There was palpable lym-
phadenopathy within the right axilla.
The patient was taken to the operating room and under-
went a right radical mastectomy. This encompassed
removal of the entire pectoralis major and minor muscu-
lature down to the right chest wall, and a complete level
III axillary lymph node dissection was performed. The
skin flaps were viable, not grossly involved with tumor,
and were able to be closed primarily (Figure 2). The
patient recovered uneventfully and was discharged two
days later. The patient developed a moderate amount of
right upper extremity chronic lymphedema.
The final pathology of the right radical mastectomy
revealed a high grade carcinosarcoma measuring 22 cm in
greatest diameter (Figures 3 &4). There was extensive cuta-
neous ulceration with underlying dermal involvement by
the tumor. The deep surgical margin of resection which
included the pectoralis major and minor muscle was neg-
ative for tumor. A total of 2 of 28 axillary lymph nodes
were positive for metastatic carcinosarcoma with extran-
odal tumor extension identified. All surgical margins were
negative for tumor. Immunohistochemical profile
revealed a neoplasm with a dimorphic histology. The epi-
thelial (carcinomatous) component stained positive for
cytokeratin immunostain CAM5.2, and the mesenchymal
(sarcomatous) component was negative for CAM5.2,
actin and desmin, but positive for vimentin. The tumor
was estrogen and progesterone receptor negative and not
amplified for the HER-2/neu gene via fluorescence in situ
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was examined by immunohistochemistry with 70% of the
cells expressing the EGFR protein, classified as moderate
staining intensity (Figure 5). Based on available data and
using AJCC criteria, the final pathologic staging was a T4b,
N1a, Mx, Stage IIIb lesion.
A post-operative whole body PET/CT fusion scan and
radionuclide bone scan showed no evidence of metastatic
disease. As per NCCN guidelines regarding her stage of
tumor, we recommended adjuvant radiation therapy to
the chest wall and axilla in addition to chemotherapy. She
received dose-dense doxorubicin and cyclophosphamide
followed by paclitaxel and subsequently radiation therapy
to the chest wall and axilla.
Patient 2
This patient is a 51 year old female who was evaluated by
her primary care provider for a tender left breast mass that
had enlarged over the previous month. The patient's past
medical history was significant for cervical cancer, and her
family history was significant for her mother dying of
ovarian cancer at the age of 57. The patient also reports
two aunts with ovarian cancer who died at the ages of 69
and 59. On physical examination, a round, mobile mass
measuring 2 cm was readily palpable at the 2 o'clock posi-
tion of the left breast, 5 cm from the nipple areola com-
plex. There was no palpable axillary lymphadenopathy.
Subsequent mammography and ultrasound examination
of the left breast revealed a hyperdense 1.6 × 1.5 × 1.1 cm
mass within the 2 o'clock position, with ill-defined and
angulated borders, assessed as a BIRADS category 4. There
was a second lesion within the 11 o'clock position of the
same breast, measuring 0.7 × 0.5 × 0.6 cm also considered
suspicious for malignancy, assessed as a BIRADS category
4. An ultrasound-guided core biopsy was performed of the
larger mass, revealing a carcinosarcoma with a few associ-
ated areas of fibroadenoma. Immunohistochemical stain-
ing revealed both an epithelial (carcinomatous)
component which stained positive for cytokeratin
CAM5.2 and a mesenchymal (sarcomatous) component
that was negative for CAM5.2, but positive for vimentin.
The patient opted for a left simple mastectomy and right
prophylactic simple mastectomy, with bilateral axillary
sentinel lymph node mappings performed. The final
pathology revealed the left simple mastectomy containing
a 2.7 cm carcinosarcoma characterized by a grade 3 epi-
thelial component with an associated, but separate, high
grade mesenchymal component (Figures 3 &4). All senti-
nel lymph nodes and surgical margins were negative for
malignancy. The final pathologic staging was a T2, N0,
MX, Stage IIa. Hormone receptor assay revealed the tumor
to be negative for both estrogen and progesterone recep-
tors, with HER-2/neu also negative. Ki-67 expression was
60%, with expression of the HER-1/EGFR receptor with a
50% strong staining intensity (Figure 5). The patient
recovered well and went on to receive adjuvant chemo-
therapy with dose-dense adriamycin (60 mg/m2) and
cyclophosphamide (600 mg/m2), followed by a full
course of Taxol.
Discussion
Carcinosarcoma of the breast (metaplastic, biphasic meta-
plastic, metaplastic sarcomatoid carcinoma, sarcomatoid
carcinoma) is an aggressive, rare neoplasm that has been
reported to account for 0.08–0.2% of all breast malignan-
cies [1-3]. Carcinosarcomas have been observed in various
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uterus. The true definition of metaplastic carcinoma of the
breast is a tumor of malignant epithelial tissue (carci-
noma) mixed with malignant cells of mesenchymal origin
(sarcoma) with apparent histologic and cytologic features
present on light microscopy and immunohistochemical
testing [3-6]. Indeed, this tumor type is often referred to as
metaplastic breast cancer, characterized as an unusual and
uncommon neoplasm that is comprised by an admixture
of two or more components [7]. The term carcinosarcoma
was previously reserved for neoplasms where the demar-
cation between carcinomatous and sarcomatous compo-
nents was distinct in all microscopic fields. The cells of
origin for this neoplasm have yet to be agreed upon, but
most research leads us to believe the cells are of myoepi-
thelial origin. The tumor components may be homogene-
ously adenosquamous, or heterogeneously epithelial
(adenocarcinoma) and mesenchymal (matrix, spindle cell
and sarcomatous) in origin [7,8]. However, it seems more
appropriate to term all breast carcinomas with obvious
carcinomatous and sarcomatous features as biphasic
metaplastic sarcomatoid carcinoma (MSC) [9].
Regardless of the name given to this entity, most meta-
plastic tumors of the breast are poorly differentiated, high
grade, highly cellular, with mitotically active pleomorphic
spindle cells. The majority are estrogen and progesterone
receptor negative, and HER2-neu negative by immunohis-
tochemistry [8]. The clinical and pathologic features of
metaplastic breast carcinomas are important to distin-
guish from other types of uncommon breast malignancies
such as spindle cell carcinoma, matrix producing carci-
noma, fibrosarcoma, osteosarcoma, malignant fibrous
histiocytoma, phylloides tumor and stromal sarcoma as
their behavior, response to treatment and survival rates
differ greatly.
Recently, Hennessy et al. reported on 100 patients with
biphasic metaplastic sarcomatoid carcinoma (MSC) and
98 patients with carcinosarcoma identified through the
SEER database. They compared clinical features and sur-
vival parameters for the two cancer types [9]. They con-
clude that both MSC and carcinosarcoma are aggressive,
treatment-refractory tumors with shared clinical features
and outcomes similar to poorly differentiated, receptor-
negative adenocarcinoma of the breast. In comparing
these two entities, they found that the initial T-stage of the
tumor had a very strong association with overall outcome.
They also identified significant differences in the meta-
static spread capacity to regional nodal basins.
Clinical features of metaplastic breast cancer are similar to
those patients with invasive ductal carcinoma. A recent
review of 16 publications over a 21-year range (1984–
2005) addressing the clinical and pathologic characteris-
tics of MSC revealed a 5-year overall survival ranging from
49–68% [7]. However, when MSC was compared to a
cohort of "typical" invasive breast cancer patients, the 5-
year disease-free and overall survival was not significantly
different (84% vs. 93%, 83%, 90%, respectively). Recur-
rence can be rapid as the primary tumor is aggressive, thus
mandating close interval follow-up after resection. Pul-
monary metastasis is more common than brain, skeletal
or hepatic metastasis, and the prognosis for these patients
is poor [10]. Outcomes for local recurrences are somewhat
improved when surgical resection is achievable. In gen-
eral, the recommended treatment options have followed
the established NCCN guidelines for patients with inva-
sive breast cancer. In the majority of the reported cases,
mastectomy with or without axillary node dissection was
performed, followed by post-operative chemotherapy and
radiation therapy in various combinations.
Evaluation of patients with breast carcinomas includes
analysis of the expression of various receptors on the pri-
mary tumor. The majority of carcinomas of the breast are
estrogen receptor positive (estimated at 75%), progester-
one receptor positive (estimated at 55%), and HER2
receptor is over-expressed (reported to be up to 25%) [7].
Adjuvant hormonal therapy and chemotherapy is based
upon the receptor status of the primary tumor and is an
important tool in treatment recommendations. The
HER1/EGFR receptor is reported to be over-expressed in
the majority of metaplastic sarcomatoid carcinomas of the
breast and should be included in the initial evaluation of
the various tumors which are described under this classi-
fication. The results may then be utilized to tailor the
adjuvant therapy based upon these findings.
New treatment opportunities may exist with the develop-
ment of agents targeting the EGFR receptor such as gefit-
inib (ZD1839, Iressa) and cetuximab (Erbitux). In a study
of 20 cases of metaplastic carcinomas of the breast, they
found that 14/20 MSC's were positive for EGFR expres-
sion, highlighting the potential utility of targeted thera-
pies to the EGFR receptor [11]. Monoclonal antibodies
and small molecule inhibitors of EGFR are currently being
evaluated in clinical trials of patients with lung and color-
ectal cancer. It has been suggested that the frequent
expression of EGFR in the absence of steroid receptors or
other receptors of the EGFR family might render meta-
plastic breast carcinomas even more sensitive to EGFR
tyrosine kinase inhibitors [12]. Further research needs to
be performed in order to fully evaluate the potential of
such therapy in patients with MSC.
Conclusion
Obtaining an accurate diagnosis of MSC is essential in
order to optimally tailor adjuvant therapy towards this
aggressive breast cancer subtype. This requires an interdis-Page 4 of 5
(page number not for citation purposes)
Cases Journal 2009, 2:15 http://www.casesjournal.com/content/2/1/15Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
ciplinary approach to treatment, with the involvement of
the entire oncology team comprised of the primary care
physician, the pathologists, surgical oncologist, radiation
oncologist, medical oncologist, and the supporting nurs-
ing and research staff. Adjuvant chemotherapy is generally
recommended utilizing established NCCN guidelines for
the more common types of breast cancer. By improving
our understanding of MSC, we may provide such patients
with novel and potentially effective treatment options
that will ultimately translate into improved overall out-
comes.
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